238 related articles for article (PubMed ID: 19491285)
41. Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy.
Tampellini M; Gned D; Baratelli C; Brizzi MP; Ottone A; Alabiso I; Bertaggia C; Di Maio M; Scagliotti GV; Veltri A
Radiol Med; 2016 Dec; 121(12):950-957. PubMed ID: 27601143
[TBL] [Abstract][Full Text] [Related]
42. Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
Link KH; Kornmann M; Leder G; Pillasch AF; Sunelaitis E; Schatz M; Pressmar J; Beger HG
Gan To Kagaku Ryoho; 1999 Feb; 26(3):269-81. PubMed ID: 10065089
[TBL] [Abstract][Full Text] [Related]
43. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66.
Alberts SR; Roh MS; Mahoney MR; O'Connell MJ; Nagorney DM; Wagman L; Smyrk TC; Weiland TL; Lai LL; Schwarz RE; Molina R; Dentchev T; Bolton JS
J Clin Oncol; 2010 Feb; 28(5):853-8. PubMed ID: 20048179
[TBL] [Abstract][Full Text] [Related]
44. Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer.
Aldrighetti L; Arru M; Ronzoni M; Salvioni M; Villa E; Ferla G
Hepatogastroenterology; 2001; 48(41):1302-7. PubMed ID: 11677951
[TBL] [Abstract][Full Text] [Related]
45. Esophageal metastasis of stem cell-subtype hepatocholangiocarcinoma: Rare presentation of a rare tumor.
Salimon M; Chapelle N; Matysiak-Budnik T; Mosnier JF; Frampas E; Touchefeu Y
World J Gastroenterol; 2018 Feb; 24(7):870-875. PubMed ID: 29467557
[TBL] [Abstract][Full Text] [Related]
46. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.
Sammon J; Fischer S; Menezes R; Hosseini-Nik H; Lewis S; Taouli B; Jhaveri K
Cancer Imaging; 2018 Feb; 18(1):8. PubMed ID: 29486800
[TBL] [Abstract][Full Text] [Related]
47. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival.
Schiffman SC; Metzger T; Dubel G; Andrasina T; Kralj I; Tatum C; McMasters KM; Scoggins CR; Martin RC
Ann Surg Oncol; 2011 Feb; 18(2):431-8. PubMed ID: 20862554
[TBL] [Abstract][Full Text] [Related]
48. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
Marquardt S; Kirstein MM; Brüning R; Zeile M; Ferrucci PF; Prevoo W; Radeleff B; Trillaud H; Tselikas L; Vicente E; Wiggermann P; Manns MP; Vogel A; Wacker FK
Eur Radiol; 2019 Apr; 29(4):1882-1892. PubMed ID: 30255257
[TBL] [Abstract][Full Text] [Related]
49. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis.
Gallagher DJ; Capanu M; Raggio G; Kemeny N
Ann Oncol; 2007 Dec; 18(12):1995-9. PubMed ID: 17962209
[TBL] [Abstract][Full Text] [Related]
50. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
51. Hepatic Artery Infusion Pump (HAIP) Therapy Versus Chemotherapy in the First-Line Setting for Patients with Unresectable Intrahepatic Cholangiocarcinoma.
Rossi AJ; Khan TM; Luna AJ; Cercek A; Jarnagin WR; Hernandez JM
Ann Surg Oncol; 2022 Jan; 29(1):35-36. PubMed ID: 34117578
[TBL] [Abstract][Full Text] [Related]
52. Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma.
Shitara K; Ikami I; Munakata M; Muto O; Sakata Y
Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):241-6. PubMed ID: 18222071
[TBL] [Abstract][Full Text] [Related]
53. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver.
O'Connell MJ; Nagorney DM; Bernath AM; Schroeder G; Fitzgibbons RJ; Mailliard JA; Burch P; Bolton JS; Colon-Otero G; Krook JE
J Clin Oncol; 1998 Jul; 16(7):2528-33. PubMed ID: 9667274
[TBL] [Abstract][Full Text] [Related]
54. Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver.
Patt YZ; Chuang VP; Wallace S; Benjamin RS; Fuqua R; Mavligit GM
Cancer; 1983 Apr; 51(8):1359-63. PubMed ID: 6186357
[TBL] [Abstract][Full Text] [Related]
55. Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.
Link KH; Sunelaitis E; Kornmann M; Schatz M; Gansauge F; Leder G; Formentini A; Staib L; Pillasch J; Beger HG
Cancer; 2001 Dec; 92(11):2746-53. PubMed ID: 11753947
[TBL] [Abstract][Full Text] [Related]
56. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
[No Abstract] [Full Text] [Related]
57. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
58. Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer.
Patt YZ; Boddie AW; Charnsangavej C; Ajani JA; Wallace S; Soski M; Claghorn L; Mavligit GM
J Clin Oncol; 1986 Sep; 4(9):1356-64. PubMed ID: 2943876
[TBL] [Abstract][Full Text] [Related]
59. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
Chung V
Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
[TBL] [Abstract][Full Text] [Related]
60. Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study.
Dhir M; Jones HL; Shuai Y; Clifford AK; Perkins S; Steve J; Hogg ME; Choudry MH; Pingpank JF; Holtzman MP; Zeh HJ; Bahary N; Bartlett DL; Zureikat AH
Ann Surg Oncol; 2017 Jan; 24(1):150-158. PubMed ID: 27431415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
